| 1.725 0.015 (0.88%) | 10-05 12:15 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.14 | 1-year : | 2.3 |
| Resists | First : | 1.83 | Second : | 1.97 |
| Pivot price | 1.77 |
|||
| Supports | First : | 1.6 | Second : | 1.33 |
| MAs | MA(5) : | 1.71  |
MA(20) : | 1.76 |
| MA(100) : | 1.8 |
MA(250) : | 2.12 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.6 |
D(3) : | 30.7 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 4.34 | Low : | 1.52 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GANX ] has closed above bottom band by 40.2%. Bollinger Bands are 28.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.78 - 1.79 | 1.79 - 1.8 |
| Low: | 1.67 - 1.68 | 1.68 - 1.7 |
| Close: | 1.69 - 1.71 | 1.71 - 1.73 |
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Thu, 01 Oct 2026
Gain Therapeutics reports stable motor scores in Parkinson’s trial - Investing.com
Thu, 01 Oct 2026
Gain Therapeutics Presents Positive Phase 1b Open-Label - globenewswire.com
Thu, 01 Oct 2026
Gain Therapeutics reports 12-month rexaceract data showing stable MDS-UPDRS and plans Phase 2 start in Q1 2027 - TradingView
Tue, 29 Sep 2026
Long-term data on a Parkinson’s drug candidate will be presented in Seoul. - Stock Titan
Thu, 17 Sep 2026
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 19.8 (%) |
| Shares Short | 2,950 (K) |
| Shares Short P.Month | 3,590 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -95.6 % |
| Return on Equity (ttm) | -268.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.23 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -3.5 |
| PEG Ratio | 0 |
| Price to Book value | 6.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|